Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Automotive & E-Mobility

Record Quarter for Blue Bird Overshadowed by Insider Selling Activity

Felix Baarz by Felix Baarz
September 5, 2025
in Automotive & E-Mobility, Earnings, Insider Trading
0
Blue Bird Stock
0
SHARES
217
VIEWS
Share on FacebookShare on Twitter

US school bus manufacturer Blue Bird has announced a blockbuster quarterly performance alongside a substantial new share repurchase initiative. However, this positive news arrives concurrently with a notable stock sale by the company’s own Chief Financial Officer, introducing a note of caution amidst the celebration.

Exceptional Financial Performance

The company’s fiscal third quarter of 2025 was marked by exceptional financial results. Net revenue surged by 19.4% to reach $398 million, decisively surpassing analyst forecasts. Even more impressive was the record-setting adjusted EBITDA of $58.5 million, which translates to a robust margin of 14.7%.

A significant driver of this growth was the electric bus division. Blue Bird delivered 271 zero-emission buses during the quarter, setting a new quarterly record. In light of this outstanding operational performance, management has raised its full-year guidance, now projecting an adjusted EBITDA of approximately $210 million.

Major Share Buyback Authorization

In a move that underscores its financial strength and confidence, Blue Bird’s board of directors has authorized a new $100 million stock repurchase program. Such initiatives are typically viewed favorably by the market, as they signal management’s belief that the shares are undervalued and directly return capital to shareholders, potentially boosting earnings per share.

Should investors sell immediately? Or is it worth buying Blue Bird?

CFO Capitalizes on Stock Highs

Contrasting the corporate optimism, CFO Razvan Radulescu elected to sell a portion of his holdings. The transaction, which occurred on September 2, involved 6,709 shares sold at a price of $57.41 per share, netting over $385,000. This sale reduces his direct stake in the company to 40,794 shares.

This insider selling activity comes at a time when Blue Bird’s stock has experienced a dramatic ascent, climbing 74.4% over the preceding six months. Transactions by corporate insiders are often scrutinized by investors for potential insights into the executive team’s view of the company’s valuation.

Analyst Confidence Remains Unshaken

Despite the CFO’s transaction, prominent Wall Street firms have maintained their bullish stances. Needham increased its price target from $49 to $53 while reiterating its “Buy” recommendation. Similarly, DA Davidson reaffirmed its positive rating. Both institutions cited the company’s superior operational execution and strong financial results as the foundation for their continued optimism.

The central question for investors now is whether the CFO’s decision represents a routine personal financial decision or a subtle indicator that the stock’s remarkable rally may be due for a pause.

Ad

Blue Bird Stock: Buy or Sell?! New Blue Bird Analysis from February 7 delivers the answer:

The latest Blue Bird figures speak for themselves: Urgent action needed for Blue Bird investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Blue Bird: Buy or sell? Read more here...

Tags: Blue Bird
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Next Post
American Axle, Manufacturing Stock

Institutional Investors Pile Into American Axle & Manufacturing Shares

Enanta Stock

Leadership Transition at Enanta Pharmaceuticals Amid Critical Milestones

KemPharm Stock

Zevra Therapeutics Shares Decline Despite Promising Drug Data

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com